Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | KRAS | P01116 | 11/20 | 0.47 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23477102 | 1.00 | NT5E (0.54) | NT5ETGM2FUT5F2POLB | |
| SCHEMBL20763305 | 0.92 | NT5E (0.58) | NT5ETGM2FUT5F2POLB | |
| SCHEMBL23476675 | 0.90 | NT5E (0.53) | NT5ETGM2FUT5F2POLB | |
| SCHEMBL19448916 | 0.85 | TGM2 (0.61) | NT5ETGM2FUT5POLBP2RY2 | |
| SCHEMBL21648046 | 0.85 | TGM2 (0.61) | NT5ETGM2FUT5POLBP2RY2 | |
| SCHEMBL25552773 | 0.83 | TGM2 (0.60) | NT5ETGM2FUT5F2POLB | |
| SCHEMBL23476832 | 0.82 | NT5E (0.48) | NT5ETGM2FUT5 | |
| SCHEMBL23542559 | 0.81 | STING1 (0.47) | NT5EFUT5 | |
| SCHEMBL23476877 | 0.81 | NT5E (0.52) | NT5ETGM2FUT5P2RY2TAS1R3 | |
| SCHEMBL19185923 | 0.81 | TGM2 (0.57) | NT5ETGM2FUT5F2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | NT5E 1329/4885TGM2 1457/4885FUT5 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.